Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Effectiveness of Interventions Targeting Self-Perception of Aging in Older Adults With Subjective Cognitive Decline

9. november 2026 oppdatert av: Zheng Li

Subjective cognitive decline (SCD) represents the initial clinical manifestation in the disease spectrum of Alzheimer's Disease (AD). It represents an essential stage for early prevention and treatment of cognitive impairment, making the SCD population an optimal target for prior intervention. This study aims to assess the feasibility and efficacy of an 8-week intervention targeting self-perception of aging in community-dwelling older adults with SCD.

Studieoversikt

Status

Fullført

Detaljert beskrivelse

Dementia, especially Alzheimer's Disease (AD), is a major healthcare issue in aging populations. It not only threatens the physical and mental health of older adults but also imposes significant economic and caregiving burdens on families and society. As a preclinical stage of AD, subjective cognitive decline (SCD) is regarded as the optimal phase for early intervention in cognitive impairment. When confronted with the threats of physical, psychological, and social aging, older adults with SCD often hold negative perceptions and emotional responses toward their own aging. They tend to attribute physical decline and memory loss to normal aging processes, overlooking controllable factors, which poses potential risks to their future cognitive outcomes, such as accelerated cognitive decline, elevated dementia risk, and increased accumulation of AD biomarkers. This study is based on the Transactional Model of Stress and Coping (TMSC) and identifies the mechanisms through which self-perception of aging influences cognitive function in older adults with SCD. A comprehensive 8-week intervention program was developed to target these mechanisms. The 8-week intervention program aims to provide practical evidence for delaying cognitive decline in older adults with SCD by enhancing their positive perceptions of aging.

Studietype

Intervensjonell

Registrering (Faktiske)

70

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100144
        • School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

60 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • aged ≥60 years;
  • residing in the community for 6 months at least;
  • experiencing a consistent decline in self-reported cognitive abilities;
  • having standard cognitive test performance in the normal range;
  • willing to participate in this study.

Exclusion Criteria:

  • having diagnosis of any neurological diseases including Parkinson's disease, brain tumor, cerebral infarction, encephalitis, epilepsy, etc.;
  • having diagnosis of mental illness such as depression, anxiety, bipolar disorder, and schizophrenia;
  • with history of substance abuse or addiction;
  • with severe visual or hearing impairment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Kontroller
Eksperimentell: 8-week intervention targeting self-perception of aging

Participants in this condition will receive an 8-week intervention targeting self-perception of aging. Group sessions will be held at community health service centers, with one session per week, each lasting 45 to 60 minutes. Additionally, homework assignments will be supplemented, and researchers will provide additional remote support via WeChat.

The intervention program aims to help older adults with subjective cognitive decline understand the aging process and adopt a positive attitude toward aging, highlighting age-related benefits. The sessions also provide emotion regulation techniques and stress-coping strategies to encourage proactive problem-solving and build confidence in handling challenges. By recalling positive life experiences, the program seeks to strengthen emotional connections, enhance the sense of belonging, and reconstruct a meaningful later life.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Subjective Cognitive Decline
Tidsramme: Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)

The 9-item Subjective Cognitive Decline Questionnaire (SCD-Q9) consists of 9 items. Higher scores indicate a greater likelihood of subjective cognitive impairment.

Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cognitive Function
Tidsramme: Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)

The Montreal Cognitive Assessment Beijing Version (MoCA-Beijing) encompasses multiple cognitive domains, including visuospatial execution ability, naming, memory and delayed recall, attention, language, abstraction, and orientation. The total score ranges from 0 to 30 points, and the higher the score, the better the overall cognitive function. Assessment tools of other cognitive domains will be used depending on the progress of the intervention program.

Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)
Self-perception of Aging
Tidsramme: Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)

The Chinese version of the Brief Aging Perceptions Questionnaire (B-APQ) comprises 17 items grouped into 5 dimensions. Participants rated their agreement on a Likert 5-point scale ranging from "strongly disagree" to "strongly agree" (1 to 5 scores). The total score ranges from 17 to 85 points, with higher scores indicating more negative self-perceived aging.

Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)
Perceived Stress
Tidsramme: Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)

The Chinese version of the Perceived Stress Scale (CPSS) will be used to measure individuals' perceived stress when facing stressful events. It consists of 14 items, with higher scores indicating higher level of perceived stress.

Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)
Coping Strategies
Tidsramme: Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)

The Simplified Coping Skill Questionnaire (SCSQ) includes two dimensions: positive coping and negative coping. Higher average scores in each dimension indicate a greater frequency of using that particular coping strategy.

Baseline (pre-intervention),8 weeks (post-intervention),and 16 weeks (follow-up)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Satisfaction questionnaire
Tidsramme: 8 weeks (post-intervention)

The satisfaction questionnaire designed by the researchers will be used.

8 weeks (post-intervention)
Compliance
Tidsramme: 8 weeks (post-intervention)

Percentage of participants who complete the whole intervention program, and the reasons for failure to comply

8 weeks (post-intervention)
Acceptability interview
Tidsramme: 8 weeks (post-intervention)

After the end of the whole intervention, semi-structured interviews will be conducted with the subjects of the intervention group who volunteered to participate in the interview.

8 weeks (post-intervention)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. november 2024

Primær fullføring (Faktiske)

30. april 2025

Studiet fullført (Faktiske)

30. april 2025

Datoer for studieregistrering

Først innsendt

27. september 2024

Først innsendt som oppfylte QC-kriteriene

1. oktober 2024

Først lagt ut (Faktiske)

2. oktober 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. april 2025

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • PUMCSON-2023-05

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere